Huaiqihuang granules
ApprovedSmall molecule
Huaiqihuang granules is one of 16 small molecule programs targeting Glomerulonephritis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Glomerulonephritis
#DrugCompanyPhaseTrials
1Thalitone
Alnylam PharmaceuticalsApproved
Fabhalta
NovartisApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Trental
VValidus Pharmaceuticals
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Phase 3
Gazyva
RochePhase 2
Darzalex
Johnson & JohnsonPhase 2
Rituxan
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glomerulonephritis1 trial
Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
Recruiting·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT04263922·466 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Huaiqihuang granules. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details